J. Goeminne

1.2k total citations
7 papers, 867 citations indexed

About

J. Goeminne is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, J. Goeminne has authored 7 papers receiving a total of 867 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 1 paper in Surgery. Recurrent topics in J. Goeminne's work include Sarcoma Diagnosis and Treatment (2 papers), Renal cell carcinoma treatment (2 papers) and HER2/EGFR in Cancer Research (2 papers). J. Goeminne is often cited by papers focused on Sarcoma Diagnosis and Treatment (2 papers), Renal cell carcinoma treatment (2 papers) and HER2/EGFR in Cancer Research (2 papers). J. Goeminne collaborates with scholars based in Belgium, Switzerland and Italy. J. Goeminne's co-authors include Andrew Wardley, Johan Nuyts, A. van Oosterom, Sandra Silberman, Ben van den Borne, Marc Martens, Raf Sciot, Herlinde Dumez, Patrick Dupont and Pascale Colé and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

J. Goeminne

7 papers receiving 844 citations

Peers

J. Goeminne

ONCOL

PRM

RNMI

CR

GASTR

Vivian Ng United States

Iris Nagelmeier Germany

Jasmeet Singh United States

N. Al-Sakaff Switzerland

Takahiro Kamio Japan

S-A. Im South Korea

Kaku Saito Japan

Takashi Nakada Japan

Marta Bonotto Italy

Shigeto Ueda Japan

Vivian Ng United States

J. Goeminne

709 ×1.5

ONCOL

404 ×1.1

PRM

376 ×1.3

RNMI

88 ×0.5

CR

93 ×0.6

GASTR

Citations per year, relative to J. Goeminne J. Goeminne (= 1×) peers Vivian Ng

Countries citing papers authored by J. Goeminne

Since Specialization

Citations

This map shows the geographic impact of J. Goeminne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Goeminne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Goeminne more than expected).

Fields of papers citing papers by J. Goeminne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Goeminne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Goeminne. The network helps show where J. Goeminne may publish in the future.

Co-authorship network of co-authors of J. Goeminne

This figure shows the co-authorship network connecting the top 25 collaborators of J. Goeminne. A scholar is included among the top collaborators of J. Goeminne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Goeminne. J. Goeminne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Demols, Anne, Ivan Borbath, Marc Van den Eynde, et al.. (2019). Exploratory analysis based on tumor location of REACHIN, a randomized, double-blinded, placebo-controlled phase 2 trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for advanced/metastatic biliary tract tumors. Annals of Oncology. 30. iv127–iv127. 2 indexed citations

2.

Dumon, Kristoffel R., Chris Verslype, Marc Peeters, et al.. (2018). Final results of a phase II quality of life (QOL) randomized, cross-over (CO) study with gemcitabine (Gem) and nab-paclitaxel (n-P) in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): QOLINPAC. Annals of Oncology. 29. viii252–viii252. 1 indexed citations

3.

Baselga, José, Patricia Gómez, Richard Greil, et al.. (2013). Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology. 31(20). 2586–2592. 298 indexed citations

4.

Gianni, Luca, Anna Lladó, Giulia Bianchi, et al.. (2010). Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer. Journal of Clinical Oncology. 28(7). 1131–1137. 187 indexed citations

5.

Seront, Emmanuel, Sylvie Rottey, Brieuc Sautois, et al.. (2010). A single arm, multicenter, phase II trial of everolimus as monotherapy in the palliative treatment of patients with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapy.. Journal of Clinical Oncology. 28(15_suppl). e15087–e15087. 5 indexed citations

6.

Stroobants, Sigrid, J. Goeminne, Saša Dimitrijević, et al.. (2003). 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®). European Journal of Cancer. 39(14). 2012–2020. 373 indexed citations

7.

Stroobants, Sigrid, J. Goeminne, Marc Martens, et al.. (2001). Early evaluation of tumour response to STI 571 with FDG-PET in patients with soft tissue sarcomas (STS). European Journal of Cancer. 37. S33–S34. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact